Pharma Stock Set to Double Today

Allakos options are flying off the shelves after upbeat drug data

Aug 5, 2019 at 10:34 AM
facebook twitter linkedin

While the broader stock market reels on ramped-up trade tensions between the U.S. and China, one equity bucking the trend in a huge way is Allakos Inc (NASDAQ:ALLK). The pharma stock is at the top of the Nasdaq this morning, more than doubling after the company's eosinophilic gastritis treatment met the goal in a mid-stage study. In addition, the company named Leo Redmond its new CFO. Against this backdrop, ALLK stock is up 118% at $67.44, and options are flying off the shelves.

Allakos shares earlier touched a record high of $70, surging past their previous all-time peak of $65.48, touched in mid-December. The security has also barreled north of recent resistance in the $45 neighborhood, set for its best day on record.

While absolute volume remains light, ALLK options are trading at a rapid-fire rate. More than 1,000 puts have changed hands already -- 18 times the average intraday volume, and on pace for an annual high. Most active is the August 60 put, where it looks like speculators are selling the contracts to open. By writing the puts, the sellers expect ALLK shares to remain north of $60 through the close on Friday, Aug. 16, when front-month options expire.

Elsewhere, a short squeeze could keep the wind at the stock's back. Short interest grew more than 11% during the most recent reporting period, and now represents more than one-third of the equity's total available float. At Allakos stock's average pace of trading, it would take shorts more than three weeks to buy back their bearish bets.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners